This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) comprises innovations in small molecule, biopharmaceutical and liquid biopsy platforms. Some of the technologies profiled include advances related to nerve-on-a-chip technology, use of artificial intelligence for drug discovery, biomarker identification, immunotherapies, mRNA vaccines, cell therapy, drug delivery, and liquid biopsy methods. The TOE also provides a comprehensive listing of key innovators in this space.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Recent Advancements in Biopharmaceutical, Small Molecule, and Liquid Biopsy Technologies
- AxoSim
- Denali Therapeutics
- Yumanity Therapeutics
- Verge Genomics
- QurAlis
- I-Mab Biopharma (Shanghai) Co. Ltd.
- Genexine Inc.
- eTheRNA Immunotherapies NV
- Rubius Therapeutics Inc.
- Rakuten Medical Inc.
- Medigene AG
- Ziopharm Oncology Inc.
- Atara Biotherapeutics Inc.
- Celldex Therapeutics Inc.
- Breath Therapeutics
- Hospital for Sick Children
- Freenome
- Invitae
- TScan Therapeutics
- Myovant Sciences
- Frequency Therapeutics
- PACT Pharma
- Myriad Genetics, Inc.
- Eli Lilly
- Exact Sciences
- Personal Genome Diagnostics
- Appendix
- Key Contacts
